21 and 22 Phase II
Peenya Industrial Area
+91 80 6655 2700
Eurofins CDMO (Contract Development & Manufacturing Organization) provides integrated, end-to-end solutions for preclinical & clinical outsourcing services for both Drug Substance and Drug Product for Biologicals and Small Molecules.
We can support your drug programs for preclinical studies, formulation screening and development, analytical development and stability studies, non-GMP and GMP sterile and non-sterile manufacturing for IND/ IMPD and NDA/ CTD.
Eurofins CDMO delivers comprehensive solutions to streamline the development and manufacturing of a variety of drug substance and drug products, delivery systems and dosage forms (oral, topical, nasal, injectable).
Eurofins CDMO, India facility, provides NCE/API development services with pharmaceutical and biotechnology applications for complex, niche, small molecule programs from preclinical to Phase III and commercial manufacturing. To support clinical phase programs, including IND-enabling projects, we offer the following services
We provide seamless transition from candidate selection to commercialisation. Our Scientists and Process Engineers have excellent experience in developing new, safe and efficient route for complex molecules. Our scientific team is well versed with spike/purge studies, impurity identification, in silico analysis to assess Potential Genotoxic Impurities (PGIs) and developing analytical methods to quantity, process safety studies, polymorph and salt screening and QbD based process development for late phase compounds.
Our team delivers high quality results within defined timelines and ensures highest level of customer satisfaction.
Asia (India) | Europe (Belgium, France) | North America (Canada, USA)
Register for our next #webinar “A Scientific Journey of a Niche API Achieving Breakthrough Status by the FDA” (February 17th). FREE registration on: https://t.co/K6l93q8yyR #CDMO #eurofins #drugdevelopment #RareDisease #FDA #Webinars pic.twitter.com/pNe0SmofPL— Eurofins CDMO (@EurofinsCDMO) February 8, 2021